2017
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.Peer-Reviewed Original ResearchMetastatic pancreatic cancer patientsPancreatic cancer patientsCancer patientsNon-cross-resistant regimensExcision repair cross-complementation group 1 proteinPhase II studyPhase 2 trialEfficacy of therapyBased treatment strategiesImmunohistochemistry targetingInsufficient tumorStudy therapyLine therapyMedian survivalCytotoxic therapyMetastatic lesionsCancer related symptomsTumor biopsiesII studyPercutaneous biopsyTumor immunohistochemistryTreatment regimensTreatment strategiesBiopsyRegimens
2012
Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001
Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.Peer-Reviewed Original ResearchComparative genomic hybridizationPhase II studyStudies of therapyMolecular profilingTreating metastatic pancreatic cancerK-rasPanel of xenograftsAneuploid tumour cell populationsMetastatic pancreatic cancerComparative genomic hybridization arrayAmerican Association for Cancer ResearchTherapeutic targetK-ras mutationsTumor cell populationGene expression microarray analysisExpression microarray analysisFocal ampliconsMetastatic lesionsMetastatic biopsiesC-kitGenomic hybridizationPancreatic cancerTumor nucleiHomozygous deletionDrug sensitivityAbstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.Peer-Reviewed Original ResearchMetastatic pancreatic cancerPhase II studyMolecular profilingPercutaneous biopsyPerformance statusPancreatic cancerNon-cross-resistant regimenOutcome of salvage therapyPatients treated with FOLFIRIRefractory metastatic pancreatic cancerMetastatic pancreatic cancer patientsSurvival rateTreating metastatic pancreatic cancerAdequate bone marrowAdequate performance statusAneuploid tumour cell populationsYear survival rateAmerican Association for Cancer ResearchEfficacy of therapyFactors of patientsTumor cell populationLong-term survivalInsufficient tumorSalvage therapyStudies of therapy